United States Biotechnology & Medical Research

Crinetics Pharmaceuticals Inc (CRNX)

Track

Over the past 90 days, Crinetics Pharmaceuticals Inc. has seen exclusively selling activity from insiders, totaling approximately $3.04 million in value. These transactions, primarily planned or proposed sales by executives and directors, occurred against a backdrop of significant stock price appreciation. No insider purchases were recorded during this period following the company's most recent results financiers.
Ticker: CRNX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Crinetics Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 2 Jul 2026
Value US$2,433,596.76 | Price 125.58 | Shares 27,756 (+18.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-07 2026-07-02 PlS Planned sale
1.4
Vivaldi Coelho Rogerio
Non-Executive Director
27,756 +18.1%
125.58
US$2,433,597 		27,756 +18.1% 125.58 US$2,433,597
2026-07-02 2026-07-02 PrS Proposed sale
2.5
JEFF KNIGHT

Officer

Officer
80,101
312.11
US$2,659,596 		80,101 312.11 US$2,659,596
2026-07-02 2026-07-02 PrS Proposed sale
1.4
ROGERIO VIVALDI COELHO

Director

Non-Executive Director
41,075
492.87
US$3,050,300 		41,075 492.87 US$3,050,300
2026-06-18 2026-06-17 PlS Planned sale
3.4
Okey Stephanie
Non-Executive Director
608 -8.7%
36.22
US$22,022 		608 -8.7% 36.22 US$22,022
2026-06-18 2026-06-17 PlS Planned sale
3.4
Okey Stephanie
Non-Executive Director
6,292 -47.3%
35.62
US$224,121 		6,292 -47.3% 35.62 US$224,121
2026-06-17 2026-06-17 PrS Proposed sale
3.4
STEPHANIE OKEY

Director

Non-Executive Director
6,900
35.00
US$241,500 		6,900 35.00 US$241,500
2026-05-04 2026-05-04 PrS Proposed sale
2.5
JEFF KNIGHT

Officer

Officer
9,485
39.02
US$370,105 		9,485 39.02 US$370,105
2026-04-14 2026-04-14 PrS Proposed sale
2.5
JEFF KNIGHT

Officer

Officer
20,900
38.66
US$807,994 		20,900 38.66 US$807,994
2026-04-13 2026-04-13 PrS Proposed sale
2.5
JEFF KNIGHT

Officer

Officer
4,434
39.44
US$174,877 		4,434 39.44 US$174,877
2026-04-10 2026-04-08 PlS Planned sale
2.5
Knight Jeff E.

Chief Dev. & Operating Officer

Officer
85,163 -44.7%
40.10
US$3,415,036 		85,163 -44.7% 40.10 US$3,415,036
2026-04-08 2026-04-08 PrS Proposed sale
2.5
JEFF KNIGHT

Officer

Officer
85,163
38.41
US$3,271,111 		85,163 38.41 US$3,271,111
2026-03-18 2026-03-18 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
24,756
37.89
US$938,005 		24,756 37.89 US$938,005
2026-03-18 2026-03-16 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
8,785 -2.1%
37.77
US$331,809 		8,785 -2.1% 37.77 US$331,809
2026-03-18 2026-03-16 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
13,196 -3.1%
37.11
US$489,704 		13,196 -3.1% 37.11 US$489,704
2026-03-18 2026-03-16 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
4,241 -3.0%
37.77
US$160,183 		4,241 -3.0% 37.77 US$160,183
2026-03-18 2026-03-16 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
6,371 -4.3%
37.11
US$236,428 		6,371 -4.3% 37.11 US$236,428
2026-03-16 2026-03-16 PrS Proposed sale
Stephen Betz

Officer

Officer
26,525
37.49
US$994,422 		26,525 37.49 US$994,422
2026-03-16 2026-03-16 PrS Proposed sale
2.5
Jeff Knight

Officer

Officer
25,113
37.49
US$941,486 		25,113 37.49 US$941,486
2026-03-16 2026-03-16 PrS Proposed sale
2.3
Richard Scott Struthers

Director; Officer

Executive Director
45,013
37.49
US$1,687,537 		45,013 37.49 US$1,687,537
2026-03-13 2026-03-12 PlS Planned sale
1.4
Vivaldi Coelho Rogerio
Non-Executive Director
523 -3.1%
36.77
US$19,231 		523 -3.1% 36.77 US$19,231
2026-03-13 2026-03-12 PlS Planned sale
1.4
Vivaldi Coelho Rogerio
Non-Executive Director
4,477 -21.0%
36.08
US$161,530 		4,477 -21.0% 36.08 US$161,530
2026-03-12 2026-03-12 PrS Proposed sale
1.4
ROGERIO VIVALDI COELHO

Director

Non-Executive Director
5,000
36.98
US$184,900 		5,000 36.98 US$184,900
2026-03-04 2026-03-03 PlS Planned sale
3.8
Schilke Tobin

Chief Financial Officer

Officer
6,713 -7.9%
39.67
US$266,305 		6,713 -7.9% 39.67 US$266,305
2026-03-04 2026-03-03 PlS Planned sale
3.4
Okey Stephanie
Non-Executive Director
3,000 -18.4%
39.67
US$119,010 		3,000 -18.4% 39.67 US$119,010
2026-03-03 2026-03-03 PrS Proposed sale
3.4
STEPHANIE S OKEY

Director

Non-Executive Director
3,000
40.68
US$122,040 		3,000 40.68 US$122,040
2026-03-02 2026-03-02 PrS Proposed sale
3.8
Tobin Schilke

Officer

Officer
6,800
41.18
US$280,000 		6,800 41.18 US$280,000
2026-02-02 2026-02-02 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
10,000
49.94
US$499,400 		10,000 49.94 US$499,400
2026-01-07 2026-01-05 PlS Planned sale
Kalofonos Isabel

Chief Commercial Officer

Officer
2,500 -75.0%
55.00
US$137,500 		2,500 -75.0% 55.00 US$137,500
2026-01-05 2026-01-05 PrS Proposed sale
ISABEL KALOFONOS

Officer

Officer
2,500
46.73
US$116,825 		2,500 46.73 US$116,825
2026-01-02 2026-01-02 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
5,000
46.55
US$232,750 		5,000 46.55 US$232,750
2025-12-03 2025-12-01 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
5,000 -7.0%
45.02
US$225,100 		5,000 -7.0% 45.02 US$225,100
2025-12-01 2025-12-01 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
5,000
45.56
US$227,800 		5,000 45.56 US$227,800
2025-11-05 2025-11-03 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
100 -0.2%
43.27
US$4,327 		100 -0.2% 43.27 US$4,327
2025-11-05 2025-11-03 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
4,900 -6.9%
42.65
US$208,985 		4,900 -6.9% 42.65 US$208,985
2025-11-03 2025-11-03 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
5,000
43.50
US$217,500 		5,000 43.50 US$217,500
2025-10-03 2025-10-01 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
5,000 -7.0%
41.81
US$209,050 		5,000 -7.0% 41.81 US$209,050
2025-10-01 2025-10-01 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
5,000
41.65
US$208,250 		5,000 41.65 US$208,250
2025-09-30 2025-09-26 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
4,000 -3.6%
45.00
US$180,000 		4,000 -3.6% 45.00 US$180,000
2025-09-30 2025-09-26 PlS Planned sale
3.8
Fust Matthew K
Non-Executive Director
16,000 -41.2%
44.75
US$716,000 		16,000 -41.2% 44.75 US$716,000
2025-09-26 2025-09-26 PrS Proposed sale
2.3
Struthers Richard Scott

Officer; Director

Executive Director
4,000
45.00
US$180,000 		4,000 45.00 US$180,000
2025-09-26 2025-09-26 PrS Proposed sale
3.8
MATTHEW K FUST

Director

Non-Executive Director
16,000
35.89
US$574,240 		16,000 35.89 US$574,240
2025-09-04 2025-09-02 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
5,000 -4.9%
32.10
US$160,500 		5,000 -4.9% 32.10 US$160,500
2025-09-02 2025-09-02 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
5,000
30.99
US$154,950 		5,000 30.99 US$154,950
2025-08-26 2025-08-22 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
30,000 -31.2%
30.43
US$912,900 		30,000 -31.2% 30.43 US$912,900
2025-08-22 2025-08-22 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
30,000
29.40
US$882,000 		30,000 29.40 US$882,000
2025-08-21 2025-08-20 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
6,492 -8.9%
29.18
US$189,437 		6,492 -8.9% 29.18 US$189,437
2025-08-20 2025-08-20 PrS Proposed sale
1.9
DANA PIZZUTI

Officer

Officer
6,492
29.43
US$191,060 		6,492 29.43 US$191,060
2025-06-16 2025-06-12 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
97,483 -49.4%
32.23
US$3,141,877 		97,483 -49.4% 32.23 US$3,141,877
2025-06-12 2025-06-12 PrS Proposed sale
STEPHEN BETZ

Officer

Officer
97,483
32.33
US$3,151,625 		97,483 32.33 US$3,151,625
2025-03-21 2025-03-19 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
291 -0.3%
34.83
US$10,136 		291 -0.3% 34.83 US$10,136
2025-03-21 2025-03-19 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
5,479 -4.8%
34.17
US$187,217 		5,479 -4.8% 34.17 US$187,217
2025-03-21 2025-03-19 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
875 -0.3%
34.83
US$30,476 		875 -0.3% 34.83 US$30,476
2025-03-21 2025-03-19 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
16,463 -4.8%
34.17
US$562,541 		16,463 -4.8% 34.17 US$562,541
2025-03-21 2025-03-19 PlS Planned sale
2.5
Knight Jeff E.

Chief Operating Officer

Officer
361 -0.4%
34.83
US$12,574 		361 -0.4% 34.83 US$12,574
2025-03-21 2025-03-19 PlS Planned sale
2.5
Knight Jeff E.

Chief Operating Officer

Officer
6,801 -7.2%
34.17
US$232,390 		6,801 -7.2% 34.17 US$232,390
2025-03-21 2025-03-19 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
127 -0.2%
34.83
US$4,423 		127 -0.2% 34.83 US$4,423
2025-03-21 2025-03-19 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
2,388 -3.2%
34.17
US$81,598 		2,388 -3.2% 34.17 US$81,598
2025-02-05 2025-02-03 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
5,000 -13.6%
39.07
US$195,350 		5,000 -13.6% 39.07 US$195,350
2025-02-03 2025-02-03 PrS Proposed sale
1.9
DANA J PIZZUTI

Officer

Officer
5,000
39.07
US$195,372 		5,000 39.07 US$195,372
2025-01-07 2025-01-03 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
15,000 -33.9%
52.09
US$781,350 		15,000 -33.9% 52.09 US$781,350
2025-01-03 2025-01-03 PrS Proposed sale
1.9
DANA J PIZZUTI

Officer

Officer
15,000
52.09
US$781,323 		15,000 52.09 US$781,323
2024-12-04 2024-12-02 PlS Planned sale
2.3
Struthers Richard Scott

President & CEO

Executive Director
10,000 -9.1%
57.57
US$575,700 		10,000 -9.1% 57.57 US$575,700
2024-12-02 2024-12-02 PrS Proposed sale
2.3
Struthers Richard Scott

Officer

Officer
10,000
57.27
US$572,700 		10,000 57.27 US$572,700
2024-11-26 2024-11-22 PlS Planned sale
2.5
Knight Jeff E.

Chief Operating Officer

Officer
501 -1.0%
56.52
US$28,317 		501 -1.0% 56.52 US$28,317
2024-10-07 2024-10-03 PlS Planned sale
1.9
Pizzuti Dana

Chief Med and Dev Officer

Officer
14,375 -33.5%
54.63
US$785,306 		14,375 -33.5% 54.63 US$785,306
2024-10-03 2024-10-03 PrS Proposed sale
1.9
DANA J PIZZUTI

Officer

Officer
14,375
54.63
US$785,322 		14,375 54.63 US$785,322
2024-09-30 2024-09-26 PlS Planned sale
1.5
Wilson Marc

CFO

Officer
25,000 -18.4%
51.11
US$1,277,750 		25,000 -18.4% 51.11 US$1,277,750
2024-09-26 2024-09-26 PrS Proposed sale
1.5
MARC WILSON

Officer

Officer
25,000
51.11
US$1,277,625 		25,000 51.11 US$1,277,625
2024-09-12 2024-09-10 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
1,035 -1.5%
51.50
US$53,302 		1,035 -1.5% 51.50 US$53,302
2024-09-10 2024-09-10 PrS Proposed sale
Betz Stephen F.

Officer; Co-Founder

Officer
1,035
51.50
US$53,301 		1,035 51.50 US$53,301
2024-08-28 2024-08-26 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
3,000 -4.1%
53.19
US$159,570 		3,000 -4.1% 53.19 US$159,570
2024-08-26 2024-08-26 PrS Proposed sale
Betz Stephen F.

Officer; Co-Founder

Officer
3,000
53.19
US$159,570 		3,000 53.19 US$159,570
2024-08-14 2024-08-12 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
3,000 -4.0%
47.68
US$143,040 		3,000 -4.0% 47.68 US$143,040
2024-08-12 2024-08-12 PrS Proposed sale
Betz Stephen F.

Officer; Co-Founder

Officer
3,000
47.68
US$143,050 		3,000 47.68 US$143,050
2024-07-26 2024-07-25 PlS Planned sale
Betz Stephen F.

Chief Scientific Officer

Officer
3,000 -3.8%
53.43
US$160,290 		3,000 -3.8% 53.43 US$160,290
Explore more

More insider trading research around Crinetics Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America